AgeX Therapeutics Reports Second Quarter 2023 Financial Results
Retrieved on:
Monday, August 14, 2023
Research, Seniors, Diabetes, Stem Cells, Biotechnology, Health, Consumer, Pharmaceutical, Science, External commercial borrowing, AgeX Therapeutics, Sino-Japanese Journalist Exchange Agreement, ASC, Interim, Tuck School of Business, Therapy, Private law, Bank statement, Audit committee, Ageing, Business, Accounting standard, Exchange, MBA, Finance, Separation, Regeneration, The Sovereign Fund of Egypt, Dartmouth University, Employment, Pre-consultation Agreement (Japan), NYSE, Compensated emancipation, Edmonton Transit Service, Pharmaceutical industry, Cryptocurrency, Security (finance), Management, MD
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
Key Points:
- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
- Cash, cash equivalents, and restricted cash totaled $0.3 million as of June 30, 2023.
- As of June 30, 2023, AgeX owed Juvenescence Limited (“Juvenescence”) $33 million in principal and origination fees on account of loans extended to AgeX.
- Operating expenses: Operating expenses for the three months ended June 30, 2023 were $1.9 million, as compared with $1.6 million for the same period in 2022.